Sign in →

Test Code BHCG Beta-Human Chorionic Gonadotropin, Quantitative, Serum

Reporting Name

Beta-HCG, Quantitative, S

Useful For

Monitoring patients for retained products of conception

 

Aiding in the diagnosis of gestational trophoblastic disease (GTD), testicular tumors, ovarian germ cell tumors, teratomas, and, rarely, other human chorionic gonadotropin (hCG)-secreting tumors

 

Serial measurement of hCG following treatment for:

-Monitoring therapeutic response in GTD or in hCG-secreting tumors

-Detecting persistent or recurrent GTD or hCG-secreting tumors

 

This test is not intended to detect or monitor pregnancy.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Ordering Guidance


If human chorionic gonadotropin (hCG) during pregnancy is indicated, order THCG / Human Chorionic Gonadotropin (hCG), Quantitative, Pregnancy, Serum.

 

If hCG testing requested on cerebrospinal fluid specimens to aid in the diagnosis of brain metastases of testicular cancer or extragonadal intracerebral germ cell tumors, order BHSF / Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid.



Specimen Required


Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.75 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days
  Ambient  7 days

Day(s) Performed

Monday through Saturday

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

84702

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BHCG Beta-HCG, Quantitative, S 21198-7

 

Result ID Test Result Name Result LOINC Value
BHCG Beta-HCG, Quantitative, S 21198-7

Clinical Information

Human chorionic gonadotropin (hCG) is a glycoprotein hormone (molecular weight: MW approximately 36,000 Da) consisting of 2 noncovalently bound subunits. The alpha subunit (92-amino acids; "naked" protein MW 10,205 Da) is essentially identical to that of luteinizing hormone (LH), follicle-stimulating hormone, and thyrotropin (previously known as thyroid-stimulating hormone: TSH). The alpha subunit is essential for receptor transactivation. The different beta subunits of the above hormones are transcribed from separate genes, show less homology, and convey the receptor-specificity of the dimeric hormones. The chorionic gonadotropin, beta gene (coding for a 145-amino acid, "naked" protein MW 15,531 Da, glycosylated subunit MW approximately 22,500 Da) is highly homologous to the beta subunit of LH and acts through the same receptor. However, while LH is a classical tropic pituitary hormone, hCG does not usually circulate in significant concentrations. In pregnant primates (including humans) it is synthesized in the placenta and maintains the corpus luteum and, hence, progesterone production, during the first trimester. Thereafter, the placenta produces steroid hormones, diminishing the role of hCG. hCG concentrations fall, leveling off around week 20, significantly above prepregnancy levels. After delivery, miscarriage, or pregnancy termination, hCG falls with a half-life of 24 to 36 hours, until prepregnancy levels are reached.

 

Outside of pregnancy, hCG may be secreted by abnormal germ cell, placental, or embryonal tissues, in particular seminomatous and nonseminomatous testicular tumors; ovarian germ cell tumors; gestational trophoblastic disease (hydatidiform mole and choriocarcinoma); and benign or malignant nontesticular teratomas. Rarely, other tumors including hepatic, neuroendocrine, breast, ovarian, pancreatic, cervical, and gastric cancers may secrete hCG, usually in relatively modest quantities.

 

During pathological hCG production, the highly coordinated secretion of alpha and beta subunits of hCG may be disturbed. In addition to secreting intact hCG, tumors may produce disproportionate quantities of free alpha-subunits or, more commonly, free beta-subunits. Assays that detect both intact hCG and free beta-hCG, including this assay, tend to be more sensitive in detecting hCG-producing tumors.

 

With successful treatment of hCG-producing tumors, hCG levels should fall with a half-life of 24 to 36 hours, and eventually return to the reference range.

Cautions

Despite strenuous efforts at standardization, different human chorionic gonadotropin (hCG) assays show only modest agreements with each other. Therefore, whenever serial monitoring of hCG concentration is required, the same assay should be used for all measurements.

 

Transient elevations of serum hCG can occur following chemotherapy in patients with susceptible tumors, due to massive tumor cell lysis; these transient elevations should not be confused with tumor progression.

 

Normal serum levels of hCG do not always exclude tumor persistence since tumors may undergo transition to differentiated teratomas, which may not produce hCG.

 

In individuals with incomplete or complete primary hypogonadism (eg, menopausal women, XXY males, surgically or medically castrated individuals who are receiving inadequate sex steroid-replacement therapy), increased luteinizing hormone (LH)-gene transcription results in minor "leaky" transcription of hCG, and hCG levels of 3 to 5 IU/L and, in some cases, levels as high as 25 IU/L, may be seen. In postmenopausal women, hCG levels ranging from 3.5 to 32 IU/L have been reported. In these cases, measurements of serum concentrations of sex hormones (LH and follicle-stimulating hormone) might be indicated.

 

End-stage renal failure is associated with up to 10-fold elevations in serum hCG levels.

 

Among immunometric assays, hCG assays have been found uniquely susceptible to heterophile antibody interference, resulting in occasional false-positive results. Our current assay has been proven robust in this respect, but rare interferences still occur. Typically, the observed false-positive elevations are modest, ranging from just above the reference range to levels of 50 to 60 IU/L. If such results are seen and are discordant with the clinical picture or other biochemical or imaging tests, then the laboratory should be alerted. Rerunning the specimen in question after additional blocking treatment may resolve the issue. For patients with apparent serum hCG concentrations above 15 to 20 IU/L, hCG should also be detectable in urine, if it is truly elevated. Failure to detect urinary hCG in such patients, supports a false-positive serum hCG test.

 

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. The presence of antibodies to streptavidin or ruthenium can rarely occur and may also interfere in this assay. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.

Report Available

1 to 3 days

Specimen Retention Time

3 months

Reject Due To

Gross hemolysis Reject
Gross lipemia OK

Method Name

Electrochemiluminescence Immunoassay (ECLIA)

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Secondary ID

61718